Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + Tebotelimab in Advanced Solid Tumors
NCT04178460Phase 1Terminated
- Sponsor
- Zai Lab
- Start
- Feb 2020
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tebotelimab in gastric cancer (GC), triple-negative breast cancer (TNBC), biliary tract carcinoma (BTC) and 1 more, sponsored by Zai Lab. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Feb 2020; status: terminated.
02
Drugs
tebotelimab
03
Conditions
gastric cancer (GC)triple-negative breast cancer (TNBC)biliary tract carcinoma (BTC)endometrial carcinoma
Beyond the preview
Go deeper on NCT04178460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178460.